"Drug Interactions" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The action of a drug that may affect the activity, metabolism, or toxicity of another drug.
| Descriptor ID |
D004347
|
| MeSH Number(s) |
G07.690.773.968
|
| Concept/Terms |
Drug Interactions- Drug Interactions
- Drug Interaction
- Interaction, Drug
- Interactions, Drug
|
Below are MeSH descriptors whose meaning is more general than "Drug Interactions".
Below are MeSH descriptors whose meaning is more specific than "Drug Interactions".
This graph shows the total number of publications written about "Drug Interactions" by people in this website by year, and whether "Drug Interactions" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 3 | 3 |
| 1996 | 0 | 5 | 5 |
| 1997 | 0 | 3 | 3 |
| 1998 | 0 | 1 | 1 |
| 1999 | 0 | 4 | 4 |
| 2000 | 1 | 9 | 10 |
| 2001 | 2 | 4 | 6 |
| 2002 | 0 | 10 | 10 |
| 2003 | 0 | 9 | 9 |
| 2004 | 0 | 8 | 8 |
| 2005 | 0 | 14 | 14 |
| 2006 | 0 | 4 | 4 |
| 2007 | 2 | 6 | 8 |
| 2008 | 1 | 6 | 7 |
| 2009 | 1 | 8 | 9 |
| 2010 | 2 | 8 | 10 |
| 2011 | 0 | 4 | 4 |
| 2012 | 1 | 5 | 6 |
| 2013 | 1 | 3 | 4 |
| 2014 | 1 | 3 | 4 |
| 2015 | 1 | 6 | 7 |
| 2016 | 1 | 1 | 2 |
| 2017 | 1 | 7 | 8 |
| 2018 | 3 | 7 | 10 |
| 2019 | 0 | 4 | 4 |
| 2020 | 0 | 5 | 5 |
| 2021 | 0 | 2 | 2 |
| 2022 | 0 | 1 | 1 |
| 2024 | 1 | 1 | 2 |
| 2025 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Drug Interactions" by people in Profiles.
-
Comparing the clinical utility of pharmacogenomic genotyping and next generation sequencing in a military health system adult medicine clinic. Pharmacogenomics. 2024; 25(16-18):637-645.
-
Maintenance therapy with a P2Y12 receptor inhibitor after cangrelor in patients with acute coronary syndrome. The ELECTRA-SIRIO 2 investigators' viewpoint. Cardiol J. 2025; 32(1):83-89.
-
Challenges and opportunities for early phase clinical trials of novel drug-radiotherapy combinations: recommendations from NRG Oncology, the American Society for Radiation Oncology (ASTRO), the American College of Radiology (ACR), the Sarah Cannon Research Institute, and the American College of Radiation Oncology (ACRO). Lancet Oncol. 2024 Oct; 25(10):e489-e500.
-
Clinical implications of combination proton pump inhibitor and triple therapies in patients with atrial fibrillation following percutaneous intervention: a guide for clinicians. Expert Rev Cardiovasc Ther. 2024 Sep; 22(9):483-491.
-
A Calculated Risk: Evaluation of QTc Drug-Drug Interaction (DDI) Clinical Decision Support (CDS) Alerts and Performance of the Tisdale Risk Score Calculator. Drug Saf. 2024 Dec; 47(12):1235-1243.
-
Ivosidenib significantly reduces triazole levels in patients with acute myeloid leukemia and myelodysplastic syndrome. Cancer. 2024 Jun 01; 130(11):1964-1971.
-
Fentanyl Toxicity Related to Concomitant Use of Ciprofloxacin and its Effects as a CYP3A4 Inhibitor. J Pain Symptom Manage. 2023 08; 66(2):e307-e309.
-
Complexity and clinical significance of drug-drug interactions (DDIs) in oncology: challenging issues in the care of patients regarding cancer-associated thrombosis (CAT). Support Care Cancer. 2022 Oct; 30(10):8559-8573.
-
Investigating Potential Drug-Drug Interactions in Pediatric and Adolescent Patients Receiving Chemotherapy. J Oncol Pharm Pract. 2022 Jun; 28(4):904-909.
-
Characterization of drug-drug interactions on the pharmacokinetic disposition of busulfan in paediatric patients during haematopoietic stem cell transplantation conditioning. Br J Clin Pharmacol. 2022 05; 88(5):2223-2235.